What happens when leukaemia stops responding to targeted drugs, and can science stay one step ahead?
End of Content.
Get the latest creative news from us about politics, business, sport and travel
End of Content.
Dr Jane Thompson is a clinical and laboratory haematologist. She completed her undergraduate studies at The University of Adelaide and is a fellow of both the Royal Australasian College of Physicians (FRACP) and the Royal College of Pathologists of Australasia (FRCPA). Dr Thompson underwent advanced training at The Royal Adelaide Hospital, Peter MacCallum Cancer Centre, and Royal Melbourne Hospital. She has research experience in iron deficiency and supplementation, and real-world costing of novel agents for treatment of haematological malignancies. She has an NHMRC supported PhD in genomics, novel fusions, rational treatment approaches, and drug resistance in Ph-like Acute Lymphoblastic Leukaemia.

Dr Jane Thompson is a clinical and laboratory haematologist. She completed her undergraduate studies at The University of Adelaide and is a fellow of both the Royal Australasian College of Physicians (FRACP) and the Royal College of Pathologists of Australasia (FRCPA). Dr Thompson underwent advanced training at The Royal Adelaide Hospital, Peter MacCallum Cancer Centre, and Royal Melbourne Hospital. She has research experience in iron deficiency and supplementation, and real-world costing of novel agents for treatment of haematological malignancies. She has an NHMRC supported PhD in genomics, novel fusions, rational treatment approaches, and drug resistance in Ph-like Acute Lymphoblastic Leukaemia.
What happens when leukaemia stops responding to targeted drugs, and can science stay one step ahead?